Toll Free: 1-888-928-9744
Published: May, 2014 | Pages:
44 | Publisher: Global Markets Direct
Industry: Pharmaceutical | Report Format: Electronic (PDF)
Lexicon Pharmaceuticals, Inc. - Product Pipeline Review - 2014 Summary Global Markets Direct's, 'Lexicon Pharmaceuticals, Inc. - Product Pipeline Review - 2014', provides an overview of the Lexicon Pharmaceuticals, Inc.'s pharmaceutical research and development focus. This report provides comprehensive information on the current therapeutic developmental pipeline of Lexicon Pharmaceuticals, Inc.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides brief overview of Lexicon Pharmaceuticals, Inc. including business description, key information and facts, and its locations and subsidiaries - The report reviews current pipeline of Lexicon Pharmaceuticals, Inc.'s human therapeutic division and enlists all their major and minor projects - The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones - Special feature on out-licensed and partnered product portfolio - The report summarizes all the dormant and discontinued pipeline projects - Latest company statement - Latest news and deals relating to the Lexicon Pharmaceuticals, Inc.'s pipeline products Reasons to buy - Evaluate Lexicon Pharmaceuticals, Inc.'s strategic position with total access to detailed information on its product pipeline - Assess the growth potential of Lexicon Pharmaceuticals, Inc. in its therapy areas of focus - Identify new drug targets and therapeutic classes in the Lexicon Pharmaceuticals, Inc.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas - Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps - Develop strategic initiatives by understanding the focus areas of Lexicon Pharmaceuticals, Inc. and exploit collaboration and partnership opportunities - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Plan mergers and acquisitions effectively by identifying the most promising pipeline of Lexicon Pharmaceuticals, Inc. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Explore the dormant and discontinued projects of Lexicon Pharmaceuticals, Inc. and identify potential opportunities in those areas - Avoid Intellectual Property Rights related issues
Table of Contents Table of Contents 2 List of Tables 4 List of Figures 4 Lexicon Pharmaceuticals, Inc. Snapshot 5 Lexicon Pharmaceuticals, Inc. Overview 5 Key Information 5 Key Facts 5 Lexicon Pharmaceuticals, Inc. - Research and Development Overview 6 Key Therapeutic Areas 6 Lexicon Pharmaceuticals, Inc. - Pipeline Review 9 Pipeline Products by Stage of Development 9 Pipeline Products - Monotherapy 10 Pipeline Products - Partnered Products 11 Partnered Products/Combination Treatment Modalities 12 Lexicon Pharmaceuticals, Inc. - Pipeline Products Glance 13 Lexicon Pharmaceuticals, Inc. - Late Stage Pipeline Products 13 Phase III Products/Combination Treatment Modalities 13 Lexicon Pharmaceuticals, Inc. - Clinical Stage Pipeline Products 14 Phase II Products/Combination Treatment Modalities 14 Phase I Products/Combination Treatment Modalities 15 Lexicon Pharmaceuticals, Inc. - Early Stage Pipeline Products 16 Preclinical Products/Combination Treatment Modalities 16 Lexicon Pharmaceuticals, Inc. - Drug Profiles 17 telotristat etiprate 17 Product Description 17 Mechanism of Action 17 R&D Progress 17 LX-1033 19 Product Description 19 Mechanism of Action 19 R&D Progress 19 LX-2931 21 Product Description 21 Mechanism of Action 21 R&D Progress 21 sotagliflozin 23 Product Description 23 Mechanism of Action 23 R&D Progress 23 LX-7101 25 Product Description 25 Mechanism of Action 25 R&D Progress 25 LX-2761 26 Product Description 26 Mechanism of Action 26 R&D Progress 26 S100-A8 27 Product Description 27 Mechanism of Action 27 R&D Progress 27 Lexicon Pharmaceuticals, Inc. - Pipeline Analysis 28 Lexicon Pharmaceuticals, Inc. - Pipeline Products by Target 28 Lexicon Pharmaceuticals, Inc. - Pipeline Products by Route of Administration 29 Lexicon Pharmaceuticals, Inc. - Pipeline Products by Molecule Type 30 Lexicon Pharmaceuticals, Inc. - Pipeline Products by Mechanism of Action 31 Lexicon Pharmaceuticals, Inc. - Recent Pipeline Updates 32 Lexicon Pharmaceuticals, Inc. - Dormant Projects 39 Lexicon Pharmaceuticals, Inc. - Company Statement 41 Lexicon Pharmaceuticals, Inc. - Locations And Subsidiaries 42 Head Office 42 Other Locations & Subsidiaries 42 Appendix 43 Methodology 43 Coverage 43 Secondary Research 43 Primary Research 43 Expert Panel Validation 43 Contact Us 44 Disclaimer 44
List of Tables Lexicon Pharmaceuticals, Inc., Key Information 5 Lexicon Pharmaceuticals, Inc., Key Facts 5 Lexicon Pharmaceuticals, Inc. - Pipeline by Indication, 2014 8 Lexicon Pharmaceuticals, Inc. - Pipeline by Stage of Development, 2014 9 Lexicon Pharmaceuticals, Inc. - Monotherapy Products in Pipeline, 2014 10 Lexicon Pharmaceuticals, Inc. - Partnered Products in Pipeline, 2014 11 Lexicon Pharmaceuticals, Inc. - Partnered Products/ Combination Treatment Modalities, 2014 12 Lexicon Pharmaceuticals, Inc. - Phase III, 2014 13 Lexicon Pharmaceuticals, Inc. - Phase II, 2014 14 Lexicon Pharmaceuticals, Inc. - Phase I, 2014 15 Lexicon Pharmaceuticals, Inc. - Preclinical, 2014 16 Lexicon Pharmaceuticals, Inc. - Pipeline by Target, 2014 28 Lexicon Pharmaceuticals, Inc. - Pipeline by Route of Administration, 2014 29 Lexicon Pharmaceuticals, Inc. - Pipeline by Molecule Type, 2014 30 Lexicon Pharmaceuticals, Inc. - Pipeline Products by Mechanism of Action, 2014 31 Lexicon Pharmaceuticals, Inc. - Recent Pipeline Updates, 2014 32 Lexicon Pharmaceuticals, Inc. - Dormant Developmental Projects,2014 39 Lexicon Pharmaceuticals, Inc., Subsidiaries 42
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.